Cypher select

Manufactured by Cordis

Sourced in United States

The Cypher Select is a lab equipment product designed for scientific research and analysis. It serves as a device for precise and controlled infusion of liquids. The Cypher Select is capable of delivering accurate dosages and flow rates, making it a versatile tool for various laboratory applications.

Automatically generated - may contain errors

Lab products found in correlation

Xience prime, by Abbott (1 mentions) Xience 5, by Abbott (1 mentions) Xience, by Abbott (1 mentions) Promus, by Boston Scientific (1 mentions) Taxus express, by Boston Scientific (1 mentions)

2 protocols using cypher select

PCI Trial for Female Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols

The design of the SPIRIT Women study was reported elsewhere.[12 (link), 13 (link)] The trial was conceived as a substudy of the main SPIRIT Women study that was registered in 2007 (NCT00496938). Subsequent changes in the original protocol were made and the randomized study was registered a separate one in 2010 (NCT01182428). Complete study protocol is available among Supporting Information files (S1 Study Protocol).
455 female patients admitted for PCI at 25 centers (22 in Europe and 3 in South America), between September 2008 and December 2009, were randomly assigned (2:1) to receive DP-EES (Xience V and Xience Prime, Abbott Vascular, Santa Clara, CA, USA) or DP-SES (Cypher Select, Cordis, Miami Lakes, Florida, USA). The trial was funded by Abbott Vascular. The study complied with the declaration of Helsinki and was approved by the institutional review board at each participating center (S1 Table). Eligible patients provided written, informed consent.

Franzone A., Zaugg S., Piccolo R., Modena M.G., Mikhail G.W., Ferré J.M., Strasser R., Grinfeld L., Heg D., Jüni P., Windecker S, & Morice M.C. (2017). A randomized multicenter trial comparing the XIENCE everolimus eluting stent with the CYPHER sirolimus eluting stent in the treatment of female patients with de novo coronary artery lesions: The SPIRIT WOMEN study. PLoS ONE, 12(8), e0182632.

+ Open protocol

+ Expand

Coronary Stent Restenosis Patterns

Check if the same lab product or an alternative is used in the 5 most similar protocols

A total of 66 ISR lesions were identified in 41 consecutive patients enrolled in this study. We found 44 ISR within G1 DES: 21 sirolimus-eluting stents (SES) (Cypher SELECT, Cordis, Miami Lakes, FL, USA) and 23 paclitaxel-eluting stents (PES) (Taxus EXPRESS and Liberté, Boston Scientific, Natick, MA, USA). We also identified 22 ISR lesions in G2 DES: of which 11 everolimus-eluting stents (EES) (9 Xience, Abbott Vascular, Santa Clara, CA, USA; and 2 Promus, Boston Scientific, Natick, MA, USA) 10 zotarolimus-eluting stents (ZES) (Resolute, Medtronic, Santa Rosa, CA, USA) and 1 biolimus-eluting stent (BES) (BioMatrix Flex, Biosensors Inc, Newport Beach, CA, USA) (Fig. 3). Coronary angiography was clinically driven in 58.2% of cases and electively scheduled in the remaining. Only 5 lesions (7.6%) required balloon pre-dilatation before OCT pullback.Fig. 3

Schematic view of enrolled stents, according to generation, eluted drug and brand. For acronyms see “Results” chapter.

Kilickesmez K., Dall'Ara G., Rama-Merchan J.C., Ghione M., Mattesini A., Vinues C.M., Konstantinidis N., Pighi M., Estevez-Loureiro R., Zivelonghi C., Lindsay A.C., Secco G.G., Foin N., De Silva R, & Di Mario C. (2014). Optical coherence tomography characteristics of in-stent restenosis are different between first and second generation drug eluting stents. International Journal of Cardiology. Heart & Vessels, 3, 68-74.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!